<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04514081</url>
  </required_header>
  <id_info>
    <org_study_id>CHN-PLAGH-BT-057</org_study_id>
    <nct_id>NCT04514081</nct_id>
  </id_info>
  <brief_title>The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma.</brief_title>
  <official_title>A Randomized, Open-label, Phase 2 Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open-label, randomized, two-arm, phase 2 study has the primary objective of comparing&#xD;
      the ORR obtained with Chidamide+Decitabine+Camrelizumab against that obtained with&#xD;
      Decitabine+Camrelizumab in patients with Hodgkin Lymphoma who were confirmed resistant to&#xD;
      Anti-PD-1 antibody therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR assess by investigators per the 2014 Lugano classification</measure>
    <time_frame>3 years</time_frame>
    <description>rate of subjects achieved objective response in all evaluable subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects with treatment-related adverse events (AEs)</measure>
    <time_frame>3 years</time_frame>
    <description>Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v5.0.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Anti-PD-1 Antibody Resistant</condition>
  <arm_group>
    <arm_group_label>Chidamide+Decitabine+Camrelizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Decitabine+Camrelizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chidamide; Decitabine; Camrelizumab</intervention_name>
    <description>Chidamide is a novel and orally active benzamide class of HDAC inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, which can Induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance.&#xD;
Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1(DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.&#xD;
Camrelizumab is a humanized anti-PD-1 monoclonal antibody.</description>
    <arm_group_label>Chidamide+Decitabine+Camrelizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine+Camrelizumab</intervention_name>
    <description>Decitabine+Camrelizumab</description>
    <arm_group_label>Decitabine+Camrelizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects must have histological confirmation of relapsed or refractory Hodgkin&#xD;
             lymphoma (HL).&#xD;
&#xD;
          2. 12 to 75 years of age.&#xD;
&#xD;
          3. ECOG performance of less than 2.&#xD;
&#xD;
          4. Life expectancy of at least 3 months.&#xD;
&#xD;
          5. Subjects with lymphoma must have at least one measureable lesion &gt;1 cm as defined by&#xD;
             lymphoma response criteria.&#xD;
&#xD;
          6. Subjects must have received Anti-PD-1 antibody therapy and were confirmed Anti-PD-1&#xD;
             antibody resistant. Subjects with autologous hematopoietic stem-cell transplantation&#xD;
             are eligible which must be more than 3 months.&#xD;
&#xD;
          7. Subjects must have adequate marrow, live, renal and heart functions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with any autoimmune disease or history of syndrome that requires&#xD;
             corticosteroids or immunosuppressive medications.&#xD;
&#xD;
          2. Serious uncontrolled medical disorders or active infections, pulmonary infection&#xD;
             especially.&#xD;
&#xD;
          3. Active alimentary tract hemorrhage or history of alimentary tract hemorrhage in 1&#xD;
             month.&#xD;
&#xD;
          4. Prior organ allograft.&#xD;
&#xD;
          5. Women who are pregnant or breastfeeding.&#xD;
&#xD;
          6. Women with a positive pregnancy test on enrollment or prior to investigational product&#xD;
             administration.&#xD;
&#xD;
          7. Subjects who are compulsorily detained for treatment of either a psychiatric or&#xD;
             physical illness.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Weidong Han, M.D.</last_name>
    <phone>+861055499341</phone>
    <email>hanwdrsw@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Biotherapeutic Department of Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weidong D Han, Doctor</last_name>
      <phone>+86-10-66937463</phone>
      <email>hanwdrsw@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>C, Doctor</last_name>
    </contact_backup>
    <investigator>
      <last_name>Weidong Han</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jing Nie</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yang Liu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qingming Yang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chunmeng Wang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Minhang Zhou</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qian Mei</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiang Li</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Liang Dong</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jie Bai</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 13, 2020</study_first_submitted>
  <study_first_submitted_qc>August 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2020</study_first_posted>
  <last_update_submitted>August 17, 2020</last_update_submitted>
  <last_update_submitted_qc>August 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Han weidong</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

